IPO registrations (S-1, F-1) · Registrants
Pluri Inc.
- SEC CIK
- 1158780 · filings on EDGAR ↗
- Former names
- PLURISTEM THERAPEUTICS INC (2008–2022); PLURISTEM LIFE SYSTEMS INC (2003–2007); AI SOFTWARE INC (2001–2003)
- Registration
- Form S-1, first filed 2026-10-06; 1 initial registration, 0 amendments
- Outcome
- Declared effective 2026-10-15
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- NV
- Business address
- MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, Haifa
- EIN
- 98-0351734
- Ticker
- PLUR (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Pluri Inc. on the corporate pages
Offering terms
- Shares offered
- 2,228,940
- Listing
- Nasdaq under the symbol PLUR
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Pluri Inc. EXACT (CIK (EXACT))
- SEC filer: Pluri Inc. EXACT (CIK (EXACT))
Filings 2
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2026-10-06 | S-1 | S-1 (registration) | Pluri Inc. | 0001213900-26-107182 ↗ |
| 2026-10-15 | EFFECT | EFFECT (declared effective) | Pluri Inc. | 9999999995-26-003262 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-06 | S-1 | registration statement | $1.50 | 2,228,940 | $3,343,410 | Nasdaq PLUR | 0 | primary document; price sentence, shares headline, proceeds computed | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Aberman Zami | Director; Director,Officer | CEO & Chairman; CEO & Co. Chairman; Co-CEO & Chairman; Executive Chairman; President and CEO | 43 | 2006–2025 | |
| Keret Yossi | Officer | Chief Financial Officer | 1 | 2006 | |
| BEN-YORAM ISRAEL | Director | 31 | 2006–2019 | ||
| BRAUN ISAAC | Director | 21 | 2006–2020 | ||
| MERETSKI SHAI | TenPercentOwner | 1 | 2006 | ||
| MERETZKI HAVA | Director | 19 | 2006–2018 | ||
| SHORRER DORON | Director | 26 | 2006–2026 | ||
| YANAY YAKY | Director,Officer; Officer | CEO & President; CFO; CFO, COO & President; CFO, Executive Vice President; Chief Executive Officer; Chief Financial Officer; Co-CEO & President; COO, CFO & President; COO & President; President, COO, CFO | 45 | 2007–2025 | |
| GERMAIN MARK | Director | 24 | 2007–2020 | ||
| Doyle Michael C. | TenPercentOwner | 2 | 2007 | ||
| Wood River Trust | TenPercentOwner | 2 | 2007 | ||
| ROSMAN NACHUM | Director | 23 | 2007–2018 | ||
| Pines Shai | Director | 9 | 2008–2011 | ||
| Kwiat Moria | Director | 11 | 2012–2020 | ||
| Gur-Lavie Boaz | Officer | CFO; Chief Financial Officer | 5 | 2014–2015 | |
| Egozi Erez | Officer | Chief Financial Officer | 4 | 2017–2018 | |
| Franco-Yehuda Chen | Officer | Chief Financial Officer | 5 | 2019–2024 | |
| CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | TenPercentOwner | 17 | 2020–2021 | ||
| Shemesh-Rasmussen Maital | Director | 5 | 2021–2025 | ||
| Levi Rami Avraham | Director | 5 | 2021–2025 | ||
| Birger Pinhas Doron | Director | 4 | 2021–2025 | ||
| Shalev Varda | Director | 2 | 2021 | ||
| Abony Lorne Kenneth | Director | 3 | 2023–2024 | ||
| Zalts Liat | Officer | Chief Financial Officer | 3 | 2024–2025 | |
| Chutzpah Holdings Ltd | Director; Director,TenPercentOwner; TenPercentOwner | 6 | 2025–2026 | ||
| Manieu Alexandre Weinstein | Director,TenPercentOwner; TenPercentOwner | 9 | 2025–2026 | ||
| Ajchenbaum Eitan | Director | 3 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-09-04 | Pluri Inc. | Biotechnology | $3,677,751 | $3,677,751 | 1 | 1 |
| 2025-03-19 | Pluri Inc. | Biotechnology | $3,500,000 | $3,500,000 | 1 | 1 |
| 2022-12-30 | Pluri Inc. | Biotechnology | $8,469,323 | $8,469,323 | 14 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Pluri Inc. | Form D private offerings | CIK (EXACT) | |
| SEC filer | Pluri Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances):
- SANGAMO THERAPEUTICS, INC CA
- ILEX ONCOLOGY INC TX
- Acorda Therapeutics, Inc. NY
- AVAX TECHNOLOGIES INC MO
- APOLLON INC PA
- TRANSCEND THERAPEUTICS INC MA
- GENITOPE CORP CA
- Eloxx Pharmaceuticals, Inc. MA
- PANACOS PHARMACEUTICALS, INC. MA
- CORIXA CORP WA
Interests: Biological Products, (No Diagnostic Substances) · Health